2015-151 – Several novel naturally processed and HLA presented influenza A/H5N1-derived peptides from a class I HLA-A0201 molecules have been identified. A mass spectrometry approach was used to identify five influenza peptides from a B-cell line (homozygous for HLA-A0201) after infection with influenza A/H5N1 virus. The immunologic relevance and specificity of these identified influenza-derived... Read More
2011-065 – Three decades after the eradication of smallpox, the threat of bioterrorism and outbreaks of emerging diseases such as monkeypox have renewed interest in the development of safe and effective next-generation poxvirus vaccines and biodefense research. Current smallpox vaccines contain live virus and are contraindicated for a large percentage of the population. Safer, yet still effective... Read More
2010-271 – The normal immune system contains T cells bearing antigen receptors which are not readily reactive to self. This invention describes a new method for activating self-reactive T cells in a peptide specific manner, a strategy designed to focus autoimmune cellular responses against cancers and persisting virus infections.
2009-131 – CD2 Binding Agents for Decreasing Suppressive Monocytes in Cancer and Sepsis CD2 binding molecules, such as alefacept, have been shown to deplete immunosuppressive monocytes (e.g., CD14+/DR- or CD14+/DRlow) in patients with lymphoma. Increased levels of immunosuppressive monocytes have been found to be associated with poor prognosis. Continued depletion of immunosuppressive monocytes appeared... Read More
2008-144 – Antibiotics fail when pathogens acquire genes that confer resistance to these drugs. This invention proposes generating vaccines specifically against the gene products of antibiotic resistance genes. These vaccines have the potential to counterselect against drug-resistant pathogens or may be used as an adjuvent to enhance drug therapy with the antibiotic by depleting the resistance gene. The... Read More
2005-237 – A protein from the fungus alternaria which induces recruitment and activation of eosinophils.
2005-172 – Serotype selective and nonpeptidic inhibitors of botulinum neurotoxin serotype A (BoNTA) have been developed. These inhibitors are effective in detoxifying botulinum neurotoxin serotype A; they can be used as therapeutics for treating food poisoning by BoNTA, overdose of BoNTA-based cosmetics such as Botox, and they can also be used as countermeausres to BoNTA-based biological weapons.
2005-165 – The use of HIV protease inhibitors in HIV negative patients increases naive T cell production, which may be useful in helping to boost immune responses. Potential uses include enhancing responses to immunizations, boosting immune function in patients with cancer, and/or immune deficiency disorders.
Discovery and Identification of Naturally Processed and Presented HLA Class II Measles Vaccine Virus Peptides
2004-011 – Two measles vaccine virus-derived peptides, from the nucleoprotein (N peptide) and Phosphoprotein P peptide). Specifically, 1) N-1 peptide: SAGKVSSTLASELG (14 amino acid peptide); 2) P-1 peptide: ASDVETAEGGEIHELLRLQ (19 amino acid peptide)
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More